The Current Role of Disease-modifying Osteoarthritis Drugs

by Selleckchem | Apr 07 2023

Contemporary treatments for osteoarthritis (OA) pursue only to alleviate the pain caused by the illness. Discovering disease-modifying osteoarthritis drugs (DMOADs) that can induce the repair and regeneration of articular tissues would be of substantial usefulness. The purpose of this manuscript is to review the contemporary role of DMOADs in managing OA. A narrative literature review on the subject, exploring the Cochrane Library and PubMed (MEDLINE) was performed. It was encountered that many publications have analyzed the impact of several DMOAD methods, including anti-cytokine therapy (tanezumab, AMG 108, adalimumab, etanercept, anakinra), enzyme inhibitors (M6495, doxycycline, cindunistat, PG-116800), growth factors (bone morphogenetic protein-7, sprifermin), gene therapy (micro ribonucleic acids, antisense oligonucleotides), peptides (calcitonin) and others (SM04690, senolitic, transient receptor potential vanilloid 4, neural EGFL-like 1, TPCA-1, tofacitinib, lorecivivint and quercitrin). Tanezumab has been demonstrated to alleviate hip and knee pain in individuals with OA but can cause major adverse events (osteonecrosis of the knee, rapid illness progression, augmented prevalence of total joint arthroplasty of involved joints, particularly when tanezumab is combined with nonsteroidal anti-inflammatory drugs. SM04690 (a Wnt inhibitor) has been demonstrated to be safe and efficacious in alleviating pain and ameliorating function as measured by the Western Ontario and McMaster Universities Arthritis Index. The intraarticular injection of lorecivivint is deemed safe and well tolerated, with no important reported systemic complications. In conclusion, even though DMOADs seem promising, their clinical effectiveness has not yet been demonstrated for managing OA. Until forthcoming studies can proved the medications' capacity to repair and regenerate tissues affected by OA, physicians should keep using treatments that only intend to alleviate pain.

Comments：

The manuscript reviewed contemporary treatments for osteoarthritis (OA) and explored the potential of disease-modifying osteoarthritis drugs (DMOADs) to induce repair and regeneration of articular tissues. The review covered several DMOAD methods, including anti-cytokine therapy, enzyme inhibitors, growth factors, gene therapy, peptides, and others.

The review found that tanezumab, an anti-cytokine therapy, has been shown to alleviate hip and knee pain in individuals with OA but can cause major adverse events such as osteonecrosis of the knee, rapid illness progression, and an increased prevalence of total joint arthroplasty of involved joints, especially when combined with nonsteroidal anti-inflammatory drugs. SM04690, a Wnt inhibitor, has been demonstrated to be safe and effective in alleviating pain and improving function as measured by the Western Ontario and McMaster Universities Arthritis Index. Lorecivivint, an intraarticular injection, is considered safe and well-tolerated, with no significant reported systemic complications.

However, the clinical effectiveness of DMOADs has not yet been demonstrated for managing OA. Until further studies can prove their ability to repair and regenerate tissues affected by OA, physicians should continue using treatments that aim to alleviate pain.

Overall, the review highlights the potential of DMOADs as a promising avenue for managing OA but also emphasizes the need for further research to establish their clinical effectiveness.